Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03706209
Recruitment Status : Recruiting
First Posted : October 15, 2018
Last Update Posted : October 15, 2018
Sponsor:
Collaborator:
Bioskin GmbH
Information provided by (Responsible Party):
MetrioPharm AG

Brief Summary:
The primary objective of this trial is to evaluate the clinical efficacy and safety of two oral doses of MP1032 (150 mg bid and 300 mg bid) when taken for 12 weeks by patients with moderate-to-severe chronic plaque psoriasis.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: MP1032 Drug: Placebo Phase 2

Detailed Description:

This trial is a randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy and safety of two oral doses of MP1032 (150 mg bid and 300 mg bid) in adult patients with moderate-to-severe chronic plaque psoriasis.

The trial design consists of a 28-day screening period, a 12-week treatment period, and subsequently a 28-day follow-up period. Each patient will have 6 visits and unscheduled visits as needed.

Approximately 150 patients (2 × 50 patients MP1032 and 50 patients placebo) who meet the entry criteria will be randomized on Day 1 to receive either 150 mg MP1032, 300 mg MP1032 or placebo orally twice daily for 12 weeks. The administration of IMP will stop after end of study (in max. 13 weeks).

PASI (Psoriasis Area and Severity Index), PGA (Physician Global Assessment) and BSA (Body Surface Area) Scores will be recorded at predefined timepoints as basis for the efficacy evaluation.

Safety parameter will be monitored from the signing of the informed consent form (ICF) until the last follow-up visit.

To evaluate systemic concentrations of MP1032 PK (pharmacokinetics) samples will be analyzed in a subgroup.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Three-arm randomized, double-blind, placebo-controlled, parallel group phase II multi-center trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: double-blind
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Double-blind, Placebo-controlled, Efficacy and Safety Trial of Two Oral Doses (150 mg Bid / 300 mg Bid) of MP1032 in Male and Female Patients With Moderate-to-Severe Chronic Plaque Psoriasis
Actual Study Start Date : February 27, 2018
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: 150 mg MP1032 bid
3 × 50 mg (150 mg) MP1032 plus 3 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
Drug: MP1032
hard gelatin capsules containing 50mg MP1032 as active ingredient

Drug: Placebo
hard gelatin capsules containing no active ingredient

Experimental: 300 mg MP1032 bid
6 × 50 mg (300 mg) MP1032 hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
Drug: MP1032
hard gelatin capsules containing 50mg MP1032 as active ingredient

Placebo Comparator: Placebo bid
6 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
Drug: Placebo
hard gelatin capsules containing no active ingredient




Primary Outcome Measures :
  1. PASI 75 (300) [ Time Frame: from treatment start (Study Day 1) to Study Day 84 ]
    Percentage of patients reaching PASI 75 in treatment group (300 mg bid) compared to placebo

  2. PASI 75 (150) [ Time Frame: from treatment start (Study Day 1) to Study Day 84 ]
    Percentage of patients reaching PASI 75 in treatment group (150 mg bid) compared to placebo

  3. PGA improvement (300) [ Time Frame: from treatment start (Study Day 1) to Study Day 84 ]
    PGA improvement rate in treatment group (300 mg bid) compared to placebo

  4. PGA improvement (150) [ Time Frame: from treatment start (Study Day 1) to Study Day 84 ]
    PGA improvement rate in treatment group (150 mg bid) compared to placebo

  5. Incidence of Adverse Events [ Time Frame: from treatment start (Study Day 1) up to 16 weeks ]
    Incidence of adverse events in treatment groups compared to placebo


Secondary Outcome Measures :
  1. PASI 50 (300) [ Time Frame: from treatment start (Study Day 1) to Study Day 84 ]
    Percentage of patients reaching PASI 50 in treatment group (300 mg bid) compared to placebo

  2. PASI 50 (150) [ Time Frame: from treatment start (Study Day 1) to Study Day 84 ]
    Percentage of patients reaching PASI 50 in treatment group (150 mg bid) compared to placebo

  3. PASI change (300) [ Time Frame: treatment start (Study Day 1), Study Days 28, 56, 84 and 112 (follow up) ]
    Mean PASI score and change to baseline in treatment group (300mg) compared to placebo

  4. PASI Change (150) [ Time Frame: treatment start (Study Day 1), Study Days 28, 56, 84 and 112 (follow up) ]
    Mean PASI score and change to baseline in treatment group (150 mg) compared to placebo

  5. Time to PASI 50/75 [ Time Frame: from treatment start (Study Day 1) to either Study Day 25, 56, 84 or 112 ]
    Time to the achievement of PASI 50 and 75, if applicable

  6. PGA Change (300) [ Time Frame: treatment start (Study Day 1), Study Days 28, 56, 84 and 112 (follow up) ]
    Mean PGA score and change to baseline in treatment group (300mg) compared to placebo

  7. PGA Change (150) [ Time Frame: treatment start (Study Day 1), Study Days 28, 56, 84 and 112 (follow up) ]
    Mean PGA score and change to baseline in treatment group (150mg) compared to placebo

  8. BSA Change (300) [ Time Frame: treatment start (Study Day 1), Study Days 28, 56, 84 and 112 (follow up) ]
    Mean BSA score and change to baseline in treatment group (300mg) compared to placebo

  9. BSA Change (150) [ Time Frame: treatment start (Study Day 1), Study Days 28, 56, 84 and 112 (follow up) ]
    Mean BSA score and change to baseline in treatment group (150mg) compared to placebo

  10. PK data - concentration of MP1032 in blood samples [ Time Frame: 15, 30, 60 and 120 minutes after morning dose on Study Days 1 and 84 ]
    Evaluation of systemic MP1032 concentrations in blood samples



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants legally competent to sign and give informed consent.
  2. Adult male and female patients between 18 years and 70 years with moderate-to-severe chronic plaque psoriasis (diagnosed by Investigator):

    1. PASI score ≥10 - ≤20 at baseline
    2. BSA score: > 10%
    3. Stable disease duration of ≥ 6 months at the initiation of IMP.
    4. topical therapy fails to control the disease
  3. Body Mass Index (BMI) between 18.5 and 34.9 kg/m2.
  4. Women of childbearing potential (WCBP) must have a negative serum pregnancy test at Screening (Visit 1). In addition, sexually active WCBP must agree to use adequate contraception throughout the trial (see Section 3.2 for more details on adequate contraception):

    1. A method with less than 1% failure rate OR
    2. Abstinence
  5. Post-menopausal women with spontaneous amenorrhea for at least 12 months and women on hormonal replacement therapy (HRT). The use of hormonal replacement therapy (HRT) during the trial is permitted, however for these patients an appropriate contraception method according to Inclusion Criterion 4 must be ensured. Sterilized women may be included (see Section 3.2 for more details on sterile definition)
  6. Male patients who are sexually active with a female partner and are not surgically sterile (vasectomy performed at least six months prior to treatment) must agree to inform their female sexual partner to use an acceptable form of birth control as described in the informed consent form. For females, an acceptable method (Pearl Index < 1%) would be to use implants, injectable, combined oral contraceptives, some intrauterine devices, or be postmenopausal, be surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy)
  7. In good health as judged by the investigator, based on medical history, physical examination, serum chemistry, hematology and urinalysis
  8. Patients must meet the following clinical laboratory criteria:

    • White blood cell count ≥3.5 × 109/L
    • Platelet count ≥100 × 109/L
    • Serum creatinine ≤1.5 × upper limit of normal (ULN); estimated glomerular filtration rate >60 mL/min
    • Total bilirubin ≤1.5 × ULN
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN
    • Hemoglobin ≥ lower limit of normal as per central laboratory reference ranges for women and men accordingly
    • No coagulopathy (International Normalized Ratio [INR] <1.5)
  9. Patients agree to minimize normal sun exposure during the course of the trial
  10. Patients are considered reliable and capable of adhering to the protocol (e.g. able to understand the patient information and complete diaries), visit schedule, or medication intake according to the judgment of the Investigator.

Exclusion Criteria:

  1. Patients with non-plaque form of psoriasis (erythrodermic, guttate, pustular form of psoriasis). Associated psoriasis arthritis is allowed provided no other in-/exclusion criteria are influenced, no forbidden concomitant therapy is required for the well -being of the patient and there is no impact on trial objectives as determined by the Investigator.
  2. Treatment with concomitant medication that may affect and provoke or aggravate psoriasis, e.g. antimalarial drugs, beta-blockers or ACE (angiotensin-converting-enzyme) inhibitors unless on a stable dose for 3 months before IMP intake.
  3. Evidence of skin conditions at the time of Screening Visit other than psoriasis that would interfere with evaluations of the effect of the IMP on psoriasis.
  4. Patients with any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the ICF, as assessed by the investigator.
  5. Pregnant or lactating women or women planning to become pregnant during the trial and / or within 28 days following the last dose of IMP.
  6. Male patients planning a partner pregnancy or sperm donation during the trial including follow up period.
  7. Known allergies to any ingredient of the IMP e.g. mannitol, macrophage modulators, or gelatin.
  8. History or symptoms of a clinically significant illness in the four weeks before first treatment and during the trial that in the opinion of the investigator may place the patient at risk by trial participation or influence the outcome of the trial. Well controlled diseases such as hypertension, hyperlipidemia, diabetes or hypothyroidism are permitted.
  9. Patients with active malignancy or history of malignancy, except for basal cell and actinic keratosis. Basal cell carcinoma of the skin or in situ cervical carcinoma that have been fully treated and show no evidence of recurrence are allowed.
  10. Positive HIV-Antibody, HBs-Antigen or HCV-Antibody-Test at screening.
  11. Previous strong sun exposure (e.g. sea holiday) within 28 days or UV treatment within 24 weeks before IMP initiation.
  12. Known photo allergy and / or experienced drug-induced photo toxicity.
  13. Elective (planned) hospitalization or medical intervention preventing patient from following the protocol requirements.
  14. Prior treatment not adhering to defined drug classes and related washout periods (Protocol table 2.)
  15. Planned use of any ultraviolet (UV) phototherapy or photochemotherapy / photosensitizing drugs during the course of the trial and within 28 days/24 weeks following the last dose of the IMP.
  16. Patients with a history of chronic alcohol or drug abuse within 6 months of IMP initiation.
  17. Patients with a blood pressure outside the given range of 160 mm Hg (systolic) and 95 mm Hg (diastolic)
  18. Patients who are employed by MetrioPharm, contract research organization (CRO) or clinical site involved in the clinical trial.
  19. Vulnerable patients (e.g. patients kept in detention).
  20. Patients who are unable to communicate, read or understand the local language, or who display another condition, which, in the Investigator's opinion, makes them unsuitable for clinical trial participation.
  21. Patient is institutionalized because of legal or regulatory order.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03706209


Contacts
Layout table for location contacts
Contact: MetrioPharm Deutschland GmbH +49303384395 ext 02 clinicaltrials@metriopharm.com

Locations
Layout table for location information
Germany
Dr. Tsianakas / Dr. Ameluxen Recruiting
Bad Bentheim, Germany
Rothaar Studien GmbH Active, not recruiting
Berlin, Germany
Dr. Johannes Niesmann / Dr. Othlinghaus Active, not recruiting
Bochum, Germany
Klinische Forschung Dresden GmbH Active, not recruiting
Dresden, Germany
MensingDerma Active, not recruiting
Hamburg, Germany
MVZ DermaKiel Terminated
Kiel, Germany
Hautarztpraxis Dres. med. Scholz, Sebastian, Schilling Terminated
Mahlow, Germany
Universitätsmedizin Mainz, Hautklinik und Poliklinik Active, not recruiting
Mainz, Germany
Klinische Forschung Schwerin (kfsn) Recruiting
Schwerin, Germany
Centroderm GmbH Active, not recruiting
Wuppertal, Germany
Poland
GynCentrum Sp. Z o.o. Not yet recruiting
Katowice, Poland
MULTIKLINIKA SALUTE Sp. z o. o. Active, not recruiting
Katowice, Poland
Provita Sp. z o.o., Centrum Medyczne Angelius Provita Recruiting
Katowice, Poland
CENTRUM MEDYCZNE PLEJADY Sp. z o. o. spółka komandytowa Recruiting
Kraków, Poland
Dermedic Jacek Zdybski Recruiting
Ostrowiec Świętokrzyski, Poland
Kliniczny Szpital Wojewódzki nr 1 im. Fryderyka Chopina w Rzeszowie, Klinika Dermatologii Recruiting
Rzeszów, Poland
Laser Clinic s.c. Andrzej Królicki, Tomasz Kochanowski Recruiting
Szczecin, Poland
DermMEDICA Sp. z o.o. Active, not recruiting
Wrocław, Poland
Dermoklinika Centrum Medyczne s.c. M.Kierstan, J.Narbutt, A.Lesiak Recruiting
Łódź, Poland
Sponsors and Collaborators
MetrioPharm AG
Bioskin GmbH

Layout table for additonal information
Responsible Party: MetrioPharm AG
ClinicalTrials.gov Identifier: NCT03706209     History of Changes
Other Study ID Numbers: MP1032-CT04
2017-003484-36 ( EudraCT Number )
First Posted: October 15, 2018    Key Record Dates
Last Update Posted: October 15, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by MetrioPharm AG:
moderate to severe
chronic
plaque psoriasis

Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases